All In Biotech

Drug Trial Radar · NCT07284420

ADAPT Forward 1 - ISA1 - a Study to Evaluate Empasiprubart IV as add-on Therapy to Efgartigimod IV in Participants With AChR-Ab Seropositive Generalized Myasthenia Gravis With a Partial Clinical Response to Efgartigimod

An ISA to Master Protocol ARGX-999-2-MG-2000 for an Exploratory, Phase 2a, Proof-of-Concept Study to Evaluate the Safety, Tolerability, and Efficacy of Empasiprubart IV as Add-On Therapy to Efgartigimod IV in Participants With AChR-Ab Seropositive Generalized Myasthenia Gravis With a Partial Clinical Response to Efgartigimod

Last checked: Nov 19, 2026Latest source record: Sep 24, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

70

Planned (sponsor's estimate)

Start

Dec 19, 2025

Primary completion

Mar 7, 2028

Study completion Mar 7, 2028

Sponsor

Lead sponsor
argenxargenx (ARGX)
Sponsor type
Industry
First posted
Dec 16, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is part of the ADAPT Forward platform study (NCT07294170). ADAPT Forward is a platform study with the aim to look at how safe different drugs are and how well they work for people with myasthenia gravis. The goal is to find the best therapeutic approach to reduce patients' side effects and improve their quality of life. The aim of this ISA1 is to evaluate the safety and therapeutic relevance of empasiprubart as add-on therapy to efgartigimod in participants with AChR-Ab seropositive generalized myasthenia gravis. The ADAPT Forward master protocol is registered on https://clinicaltrials.gov/study/NCT07294170 More information can be found here: https://clinicaltrials.argenx.com/adaptforward1

Conditions

  • AChR-Ab Seropositive Generalized Myasthenia Gravis
  • Myasthenia Gravis
  • MG
  • gMG
  • Generalized Myasthenia Gravis
  • Generalized Myasthenia Gravis (gMG)

Interventions

  • Efgartigimod IVBiological

    Intravenous infusion of efgartigimod

  • Empasiprubart IVBiological

    Intravenous infusion of empasiprubart

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of adverse events and serious adverse events in parts A and BTime frame: Up to 21 weeks

Locations

33 sites in 8 countries. Site status is shown where the registry gives one.

  • Profound Research LLC - Carlsbad

    Carlsbad, California · Recruiting

  • Visionary Investigators Network

    Miami, Florida · Recruiting

  • University of South Florida

    Tampa, Florida · Recruiting

  • Massachusetts General Hospital

    Boston, Massachusetts · Recruiting

  • Henry Ford Health Systems

    Detroit, Michigan · Recruiting

  • Profound Research LLC at Las Vegas Neurology Center

    Las Vegas, Nevada · Recruiting

  • Dent Neurologic Institute - Amherst

    Amherst, New York · Recruiting

  • University of North Caroline at Chapel Hill-170 Manning Dr

    Chapel Hill, North Carolina · Recruiting

  • Duke Early Phase Clinical Research Unit - PPDS

    Durham, North Carolina · Recruiting

  • University of Cincinnati Medical Center - Goodman St

    Cincinnati, Ohio · Recruiting

  • Ohio State Martha Morehouse Outpatient Care

    Columbus, Ohio · Recruiting

  • Erlanger Health System

    Chattanooga, Tennessee · Recruiting

  • National Neuromuscular Research Institute

    Austin, Texas · Recruiting

  • University of Texas- San Antonio - Health Science Center - PPDS

    San Antonio, Texas · Recruiting

  • UZ Leuven - PPDS

    Leuven, Belgium · Recruiting

  • Charité - Universitätsmedizin Berlin

    Berlin, Germany · Recruiting

  • Universitätsmedizin Göttingen

    Göttingen, Germany · Recruiting

  • Universitätsklinikum Würzburg

    Würzburg, Germany · Recruiting

  • Eginitio Hospital

    Athens, Greece · Recruiting

  • AHEPA University General Hospital of Thessaloniki

    Thessaloniki, Greece · Recruiting

  • Fondazione IRCCS Istituto Neurologico Carlo Besta

    Milan, Italy · Recruiting

  • AORN Antonio Cardarelli

    Naples, Italy · Recruiting

  • ASST Papa Giovanni XXIII - Ospedale Papa Giovanni XXIII

    Bergamo, Lombardy, Italy · Recruiting

  • General Hanamaki Hospital - Kajomachi

    Hanamaki, Japan · Recruiting

  • IUHW Narita Hospital

    Narita, Japan · Recruiting

  • University of Tsukuba Hospital

    Tsukuba, Ibaraki, Japan · Recruiting

  • St. Marianna University Hospital

    Kawasaki-shi, Kanagawa, Japan · Recruiting

  • National Hospital Organization Sendai Medical Center

    Sendai, Miyagi, Japan · Recruiting

  • Warszawski Uniwersytet Medyczny

    Warsaw, Poland · Recruiting

  • MICS Centrum Medyczne Bydgoszcz

    Bydgoszcz, Kuyavian-Pomeranian Voivodeship, Poland · Recruiting

  • Centrum Medyczne Neurologia Slaska

    Katowice, Silesian Voivodeship, Poland · Recruiting

  • Hospital de La Santa Creu i Sant Pau

    Barcelona, Spain · Recruiting

  • Hospital Regional Universitario de Malaga - Hospital General

    Málaga, Malaga, Spain · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.